108 related articles for article (PubMed ID: 16637075)
1. The effects of short-term oral phytoestrogen supplementation on the hypothalamic-pituitary-testicular axis in prostate cancer patients.
Rannikko A; Petas A; Raivio T; Jänne OA; Rannikko S; Adlercreutz H
Prostate; 2006 Jul; 66(10):1086-91. PubMed ID: 16637075
[TBL] [Abstract][Full Text] [Related]
2. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation.
Rannikko A; Petas A; Rannikko S; Adlercreutz H
Prostate; 2006 Jan; 66(1):82-7. PubMed ID: 16114063
[TBL] [Abstract][Full Text] [Related]
3. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
4. Hypogonadism in male patients with cancer.
Garcia JM; Li H; Mann D; Epner D; Hayes TG; Marcelli M; Cunningham GR
Cancer; 2006 Jun; 106(12):2583-91. PubMed ID: 16688773
[TBL] [Abstract][Full Text] [Related]
5. Feedback inhibition of gonadotropins by testosterone in men with hypogonadotropic hypogonadism: comparison to the intact pituitary-testicular axis in primary hypogonadism.
Shimon I; Lubina A; Gorfine M; Ilany J
J Androl; 2006; 27(3):358-64. PubMed ID: 16474013
[TBL] [Abstract][Full Text] [Related]
6. [Dynamic study of the diencephalo-hypophyseal-testicular axis in hypogonadism].
Menchini GF; Franchi F; Romanelli R; Barletta D; Luisi M
Folia Endocrinol; 1974 Feb; 27(1):21-8. PubMed ID: 4480545
[No Abstract] [Full Text] [Related]
7. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
8. Pituitary-testicular axis function, biological to immunological ratio and charge isoform distribution of pituitary LH in male rats with experimental diabetes.
Olivares A; Méndez JP; Cárdenas M; Oviedo N; Palomino MA; Santos I; Perera-Marín G; Gutiérrez-Sagal R; Ulloa-Aguirre A
Gen Comp Endocrinol; 2009 May; 161(3):304-12. PubMed ID: 19523385
[TBL] [Abstract][Full Text] [Related]
9. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
10. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis.
Safarinejad MR
J Neuroendocrinol; 2008 Dec; 20(12):1368-75. PubMed ID: 19094084
[TBL] [Abstract][Full Text] [Related]
12. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human LH and hCG on serum and urine LH and androgens in men.
Handelsman DJ; Goebel C; Idan A; Jimenez M; Trout G; Kazlauskas R
Clin Endocrinol (Oxf); 2009 Sep; 71(3):417-28. PubMed ID: 19170708
[TBL] [Abstract][Full Text] [Related]
14. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant hGH (rhGH) replacement on gonadal function in male patients with organic adult-onset GH deficiency.
Giavoli C; Ferrante E; Ermetici F; Bergamaschi S; Ronchi CL; Lania AG; Ambrosi B; Spada A; Beck-Peccoz P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):717-21. PubMed ID: 17121521
[TBL] [Abstract][Full Text] [Related]
16. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
17. Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Petrozziello A; Migliorini F; Caruso B; Cocco C; Sava T; Ghimenton C; Romano M; Monaco C; Comunale L
Anticancer Res; 2011 Mar; 31(3):1071-8. PubMed ID: 21498741
[TBL] [Abstract][Full Text] [Related]
18. Exposure to the phytoestrogen daidzein attenuates apomorphine-induced penile erection concomitant with plasma testosterone level reduction in dose- and time-related manner in adult rats.
Pan L; Xia X; Feng Y; Jiang C; Huang Y
Urology; 2007 Sep; 70(3):613-7. PubMed ID: 17905136
[TBL] [Abstract][Full Text] [Related]
19. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
20. Gonadal hormones in men with rheumatoid arthritis--from onset through 2 years.
Tengstrand B; Carlström K; Hafström I
J Rheumatol; 2009 May; 36(5):887-92. PubMed ID: 19273455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
